Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Abera Bioscience AB's PB Ratio or its related term are showing as below:
XSAT:ABERA'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 7.65
Current: 7.58
During the past 8 years, Abera Bioscience AB's highest PB Ratio was 7.65. The lowest was 0.00. And the median was 0.00.
XSAT:ABERA's PB Ratio is ranked worse than 79.95% of 1227
companies
in the Biotechnology industry
Industry Median: 2.93
vs XSAT:ABERA: 7.58
During the past 12 months, Abera Bioscience AB's average Book Value Per Share Growth Rate was 83.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -7.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 34.80% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Abera Bioscience AB was 304.70% per year. The lowest was -39.30% per year. And the median was 49.50% per year.
Back to Basics: PB Ratio
Abera Bioscience AB (XSAT:ABERA) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Abera Bioscience AB PB Ratio Related Terms
Abera Bioscience AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Abera Bioscience AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:ABERA vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Abera Bioscience AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abera Bioscience AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abera Bioscience AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Abera Bioscience AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Abera Bioscience AB (XSAT:ABERA) has a PB Ratio of 7.57 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Abera Bioscience AB and its competitors. According to the industry distribution chart, Abera Bioscience AB ranks #981 out of 1227 companies in the Biotechnology industry, placing it in the top 80%.
Is Abera Bioscience AB's PB Ratio too high?
Abera Bioscience AB's current PB Ratio is 7.57. The Biotechnology industry median PB Ratio is 2.93. Abera Bioscience AB's value of 7.57 is 158.4% above this industry median. Based on the distribution chart, Abera Bioscience AB ranks #981 out of 1227 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Abera Bioscience AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Abera Bioscience AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abera Bioscience AB ranks #981 out of 1227 companies for PB Ratio. This places Abera Bioscience AB in the lower half of its industry. The industry median PB Ratio is 2.93. Abera Bioscience AB's value of 7.57 is 158.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abera Bioscience AB's current PB Ratio of 7.57 is 158.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Abera Bioscience AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abera Bioscience AB's current PB Ratio is 7.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abera Bioscience AB stock overvalued right now?
Abera Bioscience AB (XSAT:ABERA) has a current PB Ratio of 7.57. The current PB Ratio is 7.57 and 158.4% above the Biotechnology industry median of 2.93. Abera Bioscience AB's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Abera Bioscience AB (XSAT:ABERA), the current PB Ratio is 7.57 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Abera Bioscience AB is a platform and vaccine development company based on research in the medical, molecular, and microbiological fields. The company's mission is to develop vaccine candidates based on its novel vaccine delivery platform to late pre-clinical or early clinical phase.
30GF Score
Get the complete analysis for XSAT:ABERA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ABERA has been successfully added to your 
